News
Author: Molina et al Title: CID-078, a first-in-class oral cyclin A/B-RxL inhibitor, elicits anti-tumor activity in breast cancer patient-derived xenograft models Poster Number: P2-05-29 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback